256 related articles for article (PubMed ID: 11745234)
1. Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.
Cormier JN; Patel SR; Herzog CE; Ballo MT; Burgess MA; Feig BW; Hunt KK; Raney RB; Zagars GK; Benjamin RS; Pisters PW
Cancer; 2001 Sep; 92(6):1550-5. PubMed ID: 11745234
[TBL] [Abstract][Full Text] [Related]
2. Extremity preservation by combined modality therapy in sarcomas of the hand and foot: an analysis of local control, disease free survival and functional result.
Kinsella TJ; Loeffler JS; Fraass BA; Tepper J
Int J Radiat Oncol Biol Phys; 1983 Aug; 9(8):1115-9. PubMed ID: 6307940
[TBL] [Abstract][Full Text] [Related]
3. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
4. Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.
Roeder F; Lehner B; Schmitt T; Kasper B; Egerer G; Sedlaczek O; Grüllich C; Mechtersheimer G; Wuchter P; Hensley FW; Huber PE; Debus J; Bischof M
BMC Cancer; 2014 May; 14():350. PubMed ID: 24885755
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide.
Palassini E; Ferrari S; Verderio P; De Paoli A; Martin Broto J; Quagliuolo V; Comandone A; Sangalli C; Palmerini E; Lopez-Pousa A; De Sanctis R; Bottelli S; Libertini M; Picci P; Casali PG; Gronchi A
J Clin Oncol; 2015 Nov; 33(31):3628-34. PubMed ID: 26351345
[TBL] [Abstract][Full Text] [Related]
6. Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
Bellmunt J; Eres N; Ribas A; Casado S; Albanell J; Baselga J
Cancer Chemother Pharmacol; 1997; 40(3):273-6. PubMed ID: 9219513
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Edmonson JH; Petersen IA; Shives TC; Mahoney MR; Rock MG; Haddock MG; Sim FH; Maples WJ; O'Connor MI; Gunderson LL; Foo ML; Pritchard DJ; Buckner JC; Stafford SL
Cancer; 2002 Feb; 94(3):786-92. PubMed ID: 11857314
[TBL] [Abstract][Full Text] [Related]
8. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
Dantonello TM; Int-Veen C; Harms D; Leuschner I; Schmidt BF; Herbst M; Juergens H; Scheel-Walter HG; Bielack SS; Klingebiel T; Dickerhoff R; Kirsch S; Brecht I; Schmelzle R; Greulich M; Gadner H; Greiner J; Marky I; Treuner J; Koscielniak E
J Clin Oncol; 2009 Mar; 27(9):1446-55. PubMed ID: 19224858
[TBL] [Abstract][Full Text] [Related]
9. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas.
Bokemeyer C; Franzke A; Hartmann JT; Schöber C; Arseniev L; Metzner B; Link H; Kanz L; Schmoll HJ
Cancer; 1997 Oct; 80(7):1221-7. PubMed ID: 9317171
[TBL] [Abstract][Full Text] [Related]
11. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
[TBL] [Abstract][Full Text] [Related]
12. Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.
Ryan CW; Montag AG; Hosenpud JR; Samuels B; Hayden JB; Hung AY; Mansoor A; Peabody TD; Mundt AJ; Undevia S
Cancer; 2008 Jun; 112(11):2432-9. PubMed ID: 18348295
[TBL] [Abstract][Full Text] [Related]
13. Treatment of pelvic sarcomas in adolescents and young adults with intensive combined modality therapy.
Stea B; Kinsella TJ; Triche TJ; Horvath K; Glatstein E; Miser JS
Int J Radiat Oncol Biol Phys; 1987 Dec; 13(12):1797-805. PubMed ID: 3679916
[TBL] [Abstract][Full Text] [Related]
14. Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas.
Eckert F; Gani C; Kluba T; Mayer F; Kopp HG; Zips D; Bamberg M; Müller AC
Strahlenther Onkol; 2013 Jun; 189(6):482-5. PubMed ID: 23604183
[TBL] [Abstract][Full Text] [Related]
15. [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
Ishii T; Tatezaki S; Satoh T; Yonemoto T; Umeda T; Kitoh M
Gan To Kagaku Ryoho; 1997 Nov; 24(14):2123-30. PubMed ID: 9388523
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
Mahmoud O; Dosch A; Kwon D; Pitcher JD; Conway S; Benedetto P; Fernandez G; Trent J; Temple HT; Wolfson AH
Am J Clin Oncol; 2016 Oct; 39(5):528-34. PubMed ID: 24879472
[TBL] [Abstract][Full Text] [Related]
18. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM
Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484
[TBL] [Abstract][Full Text] [Related]
20. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]